LMR Partners’s iTeos Therapeutics ITOS Stock Holding History

LMR Partners’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-550,000	Closed	-$5.48M	–	1546
2025 Q2	$5.48M	Buy	+550,000	New	+$4.43M	0.04%	417
2025 Q1	–	Sell	-22,972	Closed	-$176K	–	1506
2024 Q4	$176K	Hold	22,972	–	–	﹤0.01%	959
2024 Q3	$235K	Hold	22,972	–	–	﹤0.01%	961
2024 Q2	$341K	Hold	22,972	–	–	﹤0.01%	811
2024 Q1	$313K	Buy	+22,972	New	+$250K	﹤0.01%	814
2023 Q4	–	Sell	-17,972	Closed	-$197K	–	1056
2023 Q3	$197K	Hold	17,972	–	–	﹤0.01%	642
2023 Q2	$238K	Sell	17,972 -94,947	-84%	-$1.35M	﹤0.01%	570
2023 Q1	$1.54M	Buy	112,919 +82,700	+274%	+$1.48M	0.02%	507
2022 Q4	$590K	Hold	30,219	–	–	0.01%	823
2022 Q3	$576K	Buy	30,219 +10,000	+49%	+$230K	0.01%	845
2022 Q2	$417K	Buy	+20,219	New	+$480K	0.01%	961

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

LMR Partners's ITOS Position: Q3 2025 in Review

LMR Partners sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 550,000 shares — an estimated $5.48M sold.

LMR Partners first reported a position in ITOS in Q2 2022 and held it in 11 quarters. The position peaked at $5.48M in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

LMR Partners reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
LMR Partners sold 550,000 iTeos Therapeutics shares in Q3 2025, an estimated $5.48M.
LMR Partners first reported a position in iTeos Therapeutics in Q2 2022 and held it in 11 quarters.
LMR Partners's iTeos Therapeutics position peaked at $5.48M in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on LMR Partners's 13F filing for Q3 2025, filed 14 Nov 2025.